The effect of leptin promoter and leptin receptor gene polymorphisms on lipid profile among the diabetic population: Modulations by atorvastatin treatment and environmental factors

Journal of Endocrinological Investigation

Volumn 37, Issue 9, 2014, Pages 835-842

  Al azzam, Sayer I ^a   Khabour, Omar F ^a   Alzoubi, Karem H ^a   Alzayadeen, Raya N ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

Leptin; Leptin receptor; Lipid profile; Polymorphism; Type II diabetes

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LEPTIN; LEPTIN RECEPTOR; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HEPTANOIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN RECEPTOR, HUMAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE DURATION; DNA POLYMORPHISM; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; FEMALE; GENOTYPE; HUMAN; JORDAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DYSLIPIDEMIAS; GENETIC POLYMORPHISM; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; MIDDLE AGED; SEX DIFFERENCE;

CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; GENE-ENVIRONMENT INTERACTION; GENOTYPE; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEPTIN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PYRROLES; RECEPTORS, LEPTIN; SEX FACTORS; TRIGLYCERIDES;

EID: 84921514618     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-014-0113-6     Document Type: Article

References (45)

1. Kaul K, Tarr JM, Ahmad SI, Kohner EM, Chibber R (2012) Introduction to diabetes mellitus. Adv Exp Med Biol 771:1-11
2. Imam K (2012) Clinical features, diagnostic criteria and pathogenesis of diabetes mellitus. Adv Exp Med Biol 771:340-355
3. Imam K (2012) Management and treatment of diabetes mellitus. Adv Exp Med Biol 771:356-380
4. No author listed (1984) The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251(3):365-374
5. O'Brien T, Nguyen TT, Zimmerman BR (1998) Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 73(10):969-976. doi:10.4065/73.10.969
6. Merrin PK, Elkeles RS (1991) Treatment of diabetes: the effect on serum lipids and lipoproteins. Postgrad Med J 67(792):931-937
7. Schmitz G, Schmitz-Madry A, Ugocsai P (2007) Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Curr Opin Lipidol 18(2):164-173. doi:10.1097/MOL.0b013e328055508300041433-200704000-00008
8. Perez-Jimenez F (2008) Polymorphisms of apoprotein E and response to statins. Med Clin (Barc) 130(11):413-414 (pii: 13117856)
9. Stancakova A, Baldaufova L, Javorsky M, Kozarova M, Salagovic J, Tkac I (2006) Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome. Physiol Res 55(5):483-490 (pii: 836)
10. Xu Y, Bao Q, He B, Pan Y, Zhang R, Mao X, Tang Z, Qu L, Zhu C, Tian F, Wang S (2012) Association of angiotensin I converting enzyme, angiotensin II type 1 receptor and angiotensin I converting enzyme 2 gene polymorphisms with the dyslipidemia in type 2 diabetic patients of Chinese Han origin. J Endocrinol Invest 35(4):378-383. doi:10.3275/7797
11. Akther A, Khan KH, Begum M, Parveen S, Kaiser MS, Chowdhury AZ (2009) Leptin: a mysterious hormone; its physiology and pathophysiology. Mymensingh Med J 18(1 Suppl):S140-S144
12. Fietta P (2005) Focus on leptin, a pleiotropic hormone. Minerva Med 96(2):65-75
13. Boumaiza I, Omezzine A, Rejeb J, Rebhi L, Ouedrani A, Ben Rejeb N, Nabli N, Ben Abdelaziz A, Bouslama A (2012) Relationship between leptin G2548A and leptin receptor Q223R gene polymorphisms and obesity and metabolic syndrome risk in Tunisian volunteers. Genet Test Mol Biomarkers 16(7):726-733. doi:10.1089/gtmb.2011.0324
14. Murugesan D, Arunachalam T, Ramamurthy V, Subramanian S (2010) Association of polymorphisms in leptin receptor gene with obesity and type 2 diabetes in the local population of Coimbatore. Indian J Hum Genet 16(2):72-77. doi:10.4103/0971-6866.69350
15. Mizuta E, Kokubo Y, Yamanaka I, Miyamoto Y, Okayama A, Yoshimasa Y, Tomoike H, Morisaki H, Morisaki T (2008) Leptin gene and leptin receptor gene polymorphisms are associated with sweet preference and obesity. Hypertens Res 31(6):1069-1077. doi:10.1291/hypres.31.1069
16. Rahmouni K (2007) Differential control of the sympathetic nervous system by leptin: implications for obesity. Clin Exp Pharmacol Physiol Suppl 34 Suppl(s1):S8-S10. doi:10.1111/j.1440-1681.2007.04760.x
17. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, Smith S, Stec DE (2010) Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 285(23):17271-17276. doi:10.1074/jbc.R110.113175
18. Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim SY, Hamnvik OP, Koniaris A (2011) Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab 301(4):E567-E584. doi:10.1152/ajpendo.00315.2011
19. Fruhbeck G, Jebb SA, Prentice AM (1998) Leptin: physiology and pathophysiology. Clin Physiol 18(5):399-419
20. Moreno-Aliaga MJ, Stanhope KL, Havel PJ (2001) Transcriptional regulation of the leptin promoter by insulin-stimulated glucose metabolism in 3t3-l1 adipocytes. Biochem Biophys Res Commun 283(3):544-548. doi:10.1006/bbrc.2001.4822S0006291X01948223
21. Cusin I, Zakrzewska KE, Boss O, Muzzin P, Giacobino JP, Ricquier D, Jeanrenaud B, Rohner-Jeanrenaud F (1998) Chronic central leptin infusion enhances insulin-stimulated glucose metabolism and favors the expression of uncoupling proteins. Diabetes 47(7):1014-1019
22. O'Rahilly S (2001) Leptin: pathophysiology and implications for therapy. Eat Weight Disord 6(3 Suppl):21
23. Nieters A, Becker N, Linseisen J (2002) Polymorphisms in candidate obesity genes and their interaction with dietary intake of n-6 polyunsaturated fatty acids affect obesity risk in a sub-sample of the EPIC-Heidelberg cohort. Eur J Nutr 41(5):210-221. doi:10.1007/s00394-002-0378-y
24. Chagnon YC, Wilmore JH, Borecki IB, Gagnon J, Perusse L, Chagnon M, Collier GR, Leon AS, Skinner JS, Rao DC, Bouchard C (2000) Associations between the leptin receptor gene and adiposity in middle-aged Caucasian males from the HERITAGE family study. J Clin Endocrinol Metab 85(1):29-34
25. Betteridge DJ (2011) Lipid control in patients with diabetes mellitus. Nat Rev Cardiol 8(5):278-290. doi:10.1038/nrcardio.2011.23
26. Handelsman Y, Fonseca V, Rosenstock J (2012) Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus? Expert Rev Clin Pharmacol 5(1):43-54. doi:10.1586/ecp.11.73
27. Krssak M, Roden M (2004) The role of lipid accumulation in liver and muscle for insulin resistance and type 2 diabetes mellitus in humans. Rev Endocr Metab Disord 5(2):127-134. doi:10.1023/B:REMD.0000021434.98627.dc5267706
28. Borggreve SE, De Vries R, Dullaart RP (2003) Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 33(12):1051-1069 (pii: 1263)
29. Woodman RJ, Chew GT, Watts GF (2005) Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. Drugs 65(1):31-74 (pii: 6513)
30. Pascot A, Lemieux I, Bergeron J, Tremblay A, Nadeau A, Prud'homme D, Couillard C, Lamarche B, Despres JP (2002) HDL particle size: a marker of the gender difference in the metabolic risk profile. Atherosclerosis 160(2):399-406 (pii: S0021915001005792)
31. Ahmad Khan H (2007) Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. Acta Diabetol 44(4):193-200. doi:10.1007/s00592-007-0003-x
32. Gilani SY, Bibi S, Ahmed N, Shah SR (2010) Gender differences of dyslipidemia in type 2 diabetics. J Ayub Med Coll Abbottabad 22(3):146-148
33. Hu D, Hannah J, Gray RS, Jablonski KA, Henderson JA, Robbins DC, Lee ET, Welty TK, Howard BV (2000) Effects of obesity and body fat distribution on lipids and lipoproteins in nondiabetic American Indians: the strong heart study. Obes Res 8(6):411-421. doi:10.1038/oby.2000.51
34. Lee WL, Cheung AM, Cape D, Zinman B (2000) Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 23(7):962-968
35. Maple-Brown LJ, Ye C, Retnakaran R (2013) Area-under-the-HbA1c-curve above the normal range and the prediction of microvascular outcomes: an analysis of data from the Diabetes Control and Complications Trial. Diabet Med 30(1):95-99. doi:10.1111/dme.12004
36. Padros G, Ferrer A, Formiga F, Almeda J, March MA, Pujol R (2012) Dyslipidemia and ischemic cardiopathy associated with duration of diabetes mellitus in the oldest old: the OCTABAIX study. J Am Geriatr Soc 60(8):1594-1596. doi:10.1111/j.1532-5415.2012.04087.x
37. Nassar PO, Walker CS, Salvador CS, Felipetti FA, Orrico SR, Nassar CA (2012) Lipid profile of people with diabetes mellitus type 2 and periodontal disease. Diabetes Res Clin Pract 96(1):35-39. doi:10.1016/j.diabres.2011.11.017
38. Ginsberg HN, MacCallum PR (2009) The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 4(2):113-119. doi:10.1111/j.1559-4572.2008.00044.x
39. Hinuy HM, Hirata MH, Sampaio MF, Armaganijan D, Arazi SS, Salazar LA, Hirata RD (2010) Relationship between variants of the leptin gene and obesity and metabolic biomarkers in Brazilian individuals. Arq Bras Endocrinol Metabol 54(3):282-288 (pii: S0004-27302010000300006)
40. Meier U, Gressner AM (2004) Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 50(9):1511-1525. doi:10.1373/clinchem.2004.032482clinchem.2004.032482
41. Lee J, Taneja V, Vassallo R (2012) Cigarette smoking and inflammation: cellular and molecular mechanisms. J Dent Res 91(2):142-149. doi:10.1177/0022034511421200
42. World Health Organization (2009) The tobacco epidemic. A global public health emergency. Tobacco or Health Programme on Substance Abuse, Tob. Alert Spec. WHO, Geneva, Switzerland, p 28
43. Venkatesan A, Hemalatha A, Bobby Z, Selvaraj N, Sathiyapriya V (2006) Effect of smoking on lipid profile and lipid peroxidation in normal subjects. Indian J Physiol Pharmacol 50(3):273-278
44. Kharb S, Singh GP (2000) Effect of smoking on lipid profile, lipid peroxidation and antioxidant status in normal subjects and in patients during and after acute myocardial infarction. Clin Chim Acta 302(1-2):213-219 (pii: S0009898100003430)
45. Neki NS (2002) Lipid profile in chronic smokers - a clinical study. JIACM 3(1):51-54